Haemonetics Corporation (NYSE: HAE), a global medical technology company that says it is focused on delivering innovative haematology solutions to drive better patient outcomes, has opened its new global headquarters in Boston, it was reported yesterday.
The new premises are intended support the company's work to build a collaborative, performance-driven culture, bringing together its corporate and commercial teams side by side with its research and development organisation in a contemporary environment.
The new Boston location occupies more than 62,000 square feet across four floors at 125 Summer Street, a modern, LEED Gold and Energy Star certified office tower.
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
Ribo and Madrigal sign global siRNA licensing deal
Galderma launches Restylane Defyne and Refyne in Japan
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
AsymBio builds integrated platforms across biopharmaceutical development lifecycle
Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI
Cumulus Neuroscience enters Japanese market with Shionogi collaboration
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
CiteAb launches new scientific image search tool and improved reagent search engine
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
BioArctic and Eisai secure Priority Review in China for subcutaneous Leqembi
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia